Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report
Trametinib use after platinum-based chemotherapy for Low Grade Serous Ovarian Cancer

About this release

This release by Public Health Scotland (PHS) uses information from the National SACT dataset.

The aim of this work was to capture real-world evidence from Scotland on the use of trametinib for recurrent or progressive low grade serous (LGS) ovarian cancer after at least one line of platinum-based chemotherapy. The population includes patients who started treatment with trametinib, after platinum-based chemotherapy, for LGS ovarian cancer from 1st January 2019 to 31st March 2024, followed up until 30th June 2024.

The objectives were to:

• Describe the baseline characteristics of patients receiving trametinib for LGS ovarian cancer after platinum-based chemotherapy
• Describe treatment characteristics including mean and median duration of treatment and dose modification details
• Provide information on treatment pathways including prior and subsequent systemic anti-cancer therapy (SACT)
• Estimate median overall survival (mOS) from the start of trametinib treatment.

Main points

• This report provides descriptive information on the 20 patients prescribed trametinib for Low Grade Serous (LGS) ovarian cancer from 2019-2024 in clinical practice after platinum-based chemotherapy
• The estimated median overall survival (mOS) for patients who received trametinib for LGS ovarian cancer was 13.4 months (95%CI 10.3 - 34.9)
• At the time of the censor date (30th June 2024), 15 (75%) patients had died
• The median treatment duration was 4.6 months (interquartile range (IQR) 2.3 - 9.0)).

Background

Cancer Medicines Outcome Programme (CMOP) Background

The overall vision of the Cancer Medicines Outcomes Programme - Public Health Scotland (CMOP-PHS) collaboration is to better understand the real-life impact of cancer medicines on cancer patients in Scotland. Healthcare professionals may then use these findings to help support clinical decision making and enable a more bespoke and individualised approach to the provision of cancer care for all our patients. Developing, and refining, a robust and reliable process means that cancer medicines intelligence may be routinely generated to support informed decision making at individual, local, and national levels.

Together with information available from clinical trials, this additional knowledge is intended to help NHS Scotland deliver a more personalised approach to providing cancer care, and to help ensure the safe and effective use of medicines.

The CMOP-PHS collaboration builds on established clinical engagement across NHS Scotland Health Boards and integrates with key stakeholders, thereby bringing together clinical, academic and data analysis skills from the NHS, Public Health Scotland, and academia, alongside the patient and public voice. The collaboration provides organisational memory and supports workforce resilience, embedding robust processes to routinely generate and report real-world evidence (RWE). This supports the provision of patient-centred cancer care and decision-making processes, setting Scotland apart as a centre of excellence in the cancer medicines RWE arena.

National Cancer Medicines Advisory Group

The National Cancer Medicines Advisory Group (NCMAG) programme is a Health Technology Assessment (HTA) programme which provides advice to NHS Scotland on the clinical effectiveness and value for money of cancer medicines uses.

Cancer medicines that are used ‘off-label’ and or ‘off-patent’ are outside the remit of Scottish Medicines Consortium (SMC). NCMAG considers requests for uses of these cancer medicines on a national basis. Across NHS Scotland this means: greater efficiency; standardisation in decision making through a ‘Once for Scotland’ process; consistent patient access to beneficial cancer medicines; improved value for money.

NCMAG published their advice on the use of trametinib for LGS ovarian cancer following at least one platinum-based chemotherapy on 24 October 2024.